A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Pharmacokinetics, Safety, Tolerability, and Efficacy of Olatorepatide, a GLP-1/GIP Receptor Agonist, in Participants Living With Overweight or Obesity in the US
Latest Information Update: 03 Mar 2026
At a glance
- Drugs HS 20094 (Primary)
- Indications Obesity
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Regeneron Pharmaceuticals
Most Recent Events
- 03 Mar 2026 New trial record